A NOVEL HORMONE THAT PROMOTES BONE RESORPTION AND USES THEREOF

摘要

The disclosure describes the use of anti-IGFBPl antibodies to inhibit the bone loss-inducing properties of FGF21. This can be applied in the context of FGF21 treatment for obesity and/or diabetes, or in menopause-induced bone loss, such as osteoporosis.